FY2025 · ended Dec 31, 2025 · Revenue $502.73M, +27.8% YoY · Filed Mar 12, 2026
Starling Oncology, Inc. (STLN) files with the SEC under industry code 8011, Services-Offices & Clinics of Doctors of Medicine. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $502.7 million and a net loss of $60.6 million. Free cash flow was -$27.8 million. As of Jun 30, 2026 it held $41.1 million in cash and investments and $104.5 million in total debt.
Revenue (TTM)
$587.24M
+38.4% vs year-ago TTM
Net income (TTM)
$-36.29M
+44.9% vs year-ago TTM
Operating cash flow (TTM)
$328,000
+103.2% vs year-ago TTM
Free cash flow (TTM)
$-3.29M
+74.9% vs year-ago TTM
EPS (TTM)
$-0.30
+55.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
98.84M
+30.5% vs prior year
Net cash
$-63.43M
as of Jun 30, 2026
Operating margin
-4.4%
FY 2026
Company profile
- Industry
- Services-Offices & Clinics of Doctors of Medicine (SIC 8011)
- Listed as
- STLN (Nasdaq), DFPH (OTC), STLNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cerritos, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1799191
- Former names
- Oncology Institute, Inc. (until Aug 3, 2026); DFP HEALTHCARE ACQUISITIONS CORP. (until Nov 12, 2021)
Other Services-Offices & Clinics of Doctors of Medicine companies
- Hims & Hers Health, Inc. HIMS
- Teladoc Health, Inc. TDOC
- SBC Medical Group Holdings Inc SBC
- Auna S.A. AUNA
- Airsculpt Technologies, Inc. AIRS
- LifeMD, Inc. LFMD
- Westin Acquisition Corp WSTN
- Basel Medical Group Ltd BMGL
All 12 Services-Offices & Clinics of Doctors of Medicine companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $502.7M | $393.4M | $324.2M | $252.5M | $203.0M |
| Operating income | -$36.1M | -$60.1M | -$77.0M | -$82.0M | -$45.9M |
| Net income | -$60.6M | -$64.7M | -$83.1M | $152,000 | -$10.9M |
| Diluted EPS | -$0.54 | -$0.71 | -$0.92 | -$0.21 | -$0.16 |
| Operating cash flow | -$24.6M | -$26.5M | -$36.3M | -$61.8M | -$32.7M |
| Free cash flow | -$27.8M | -$30.3M | -$40.9M | -$67.3M | -$35.5M |
| Total assets | $164.7M | $172.7M | $209.2M | $261.7M | $203.4M |
| Total liabilities | $180.4M | $169.1M | $152.2M | $138.5M | $99.3M |
| Stockholders' equity | -$15.7M | $3.6M | $57.0M | $123.2M | $104.2M |
| Cash and investments | $33.6M | $49.7M | $82.9M | $132.2M | $115.2M |
| Total debt | $103.8M | $123.3M | $119.8M | $108.4M | $183,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 2, 2026 | Sep 1, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Aug 21, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 3, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Regulation FD disclosure
|
Jul 7, 2026 | Jul 1, 2026 |
All 543 Starling Oncology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.